Kentucky Trust Co Invests $39,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kentucky Trust Co acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, Holdings Channel reports. The fund acquired 365 shares of the medical equipment provider’s stock, valued at approximately $39,000.

Other institutional investors have also modified their holdings of the company. Stonebridge Financial Group LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $25,000. Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $28,000. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $35,000. Finally, R Squared Ltd purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $63,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Truist Financial reiterated a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday. Barclays reduced their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday. Raymond James reduced their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $98.98 on Thursday. The stock has a market cap of $19.70 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company’s 50-day moving average price is $106.91 and its 200 day moving average price is $107.91. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the business posted $2.20 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.97%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.